The finding rests on a deceptively simple biological insight. Cancer cells are addicted to nucleotides, the raw material of DNA and RNA, and they ramp up ribonucleotide production by 6 to 11-fold compared with normal proliferating cells to fuel their relentless division, metastasis, and drug resistance. But this hyperactive metabolism creates a vulnerability: when the balance between ribonucleotides and deoxyribonucleotides is thrown off, mitochondria become stressed, and their DNA — normally sealed inside these energy-producing organelles — leaks into the cytosol. The innate immune sensor cGAS recognizes this misplaced DNA and activates the STING pathway, prompting the cancer cell to pump out type I interferons and recruit the immune system against itself.

Fluoropyrimidines already exploit this logic in part. As antimetabolites, they disrupt nucleotide synthesis, damage DNA, and can ignite cGAS–STING signaling. Yet their clinical power has long been blunted by two problems: they are metabolically unstable, and they must compete with the supraphysiological pools of endogenous nucleotides that cancer cells maintain. Despite decades of optimization — enzyme inhibitors, the prodrug capecitabine, the S-1 regimen, trifluridine-tipiracil — outcomes in advanced colorectal cancer, which kills roughly 700,000 people each year, remain stubbornly poor. The Nanjing University-led team hypothesized that rather than fighting the tumor’s nucleotide surplus, they could weaponize it.

Through systematic screening of nucleotide combinations with floxuridine, they discovered that pyrimidine ribonucleotides — especially CMP — transformed the drug’s activity. The synergy was strikingly specific: CMP alone did nothing, and it barely enhanced the widely used drug 5-fluorouracil or its metabolite fluorouridine. Only floxuridine and its active metabolite FdUMP, which feed directly into deoxyribonucleotide metabolism, responded. This selectivity traces to metabolic partitioning: 5-fluorouracil preferentially enters RNA metabolism, while floxuridine is channeled toward FdUMP, the molecule that covalently inhibits thymidylate synthase, the enzyme that makes the essential DNA building block TMP.

CRISPR–Cas9 library screening revealed exactly which enzymes were holding floxuridine back. Five pyrimidine metabolism genes — CMPK1, CMPK2, TYMP, UPP1, and UPP2 — emerged as the top hits that, when lost, made cells more sensitive to the drug. Analyzing over 4,700 patient samples from The Cancer Genome Atlas, the team showed that patients whose tumors expressed low levels of these five genes survived significantly longer, underscoring their clinical relevance. Remarkably, CMP and its intracellular metabolites, including uridine and 2′-deoxyuridine, were able to engage all five enzymes simultaneously, as demonstrated by drug affinity responsive target stability assays. No existing small-molecule inhibitor achieves this multi-target blockade, and developing one would be costly and unpredictable.

The metabolic consequences were dramatic. Liquid chromatography–tandem mass spectrometry showed that CMP boosted peak intracellular FdUMP levels nearly 500-fold and extended the metabolite’s half-life from 0.14 hours to 3.45 hours — a more than 20-fold increase in persistence. Cellular thermal shift assays confirmed that the accumulated FdUMP bound and stabilized thymidylate synthase more effectively, deepening the blockade of TMP synthesis. When the team supplemented cells with TMP itself, the synergy vanished entirely, proving the mechanism runs through thymineless death rather than direct interference with DNA replication. Purine nucleotides, by contrast, were cytotoxic at high concentrations and offered no benefit.

Depleted TMP synthesis triggered exactly the mitochondrial crisis the researchers predicted. Quantitative PCR along the mitochondrial genome revealed a position-dependent gradient of copy-number loss spreading from the replication origin — a molecular fingerprint of stalled replication forks. Damaged mitochondrial DNA then escaped into the cytosol, largely through VDAC1 channels: blocking VDAC1 oligomerization with the inhibitor VBIT-4 suppressed the interferon response just as effectively as depleting mitochondrial DNA altogether. Pharmacological inhibition of cGAS with RU.521 or of STING with H-151 likewise shut down the signal, and tumors grew poorly in response to the combination only in mice with functional STING.

Translating the chemistry into a clinic-ready formulation required solving a delivery dilemma. CMP and FdUMP are both highly hydrophilic, poorly permeable molecules, and the synergy collapsed when dosing intervals exceeded two hours — evidence that the two must be metabolized inside the same cell at the same time. The team exploited metal coordination chemistry, discovering that ferric iron could bridge the phosphate groups of CMP and FdUMP into self-assembling nanoscale coordination polymers. Wrapped in a PEGylated lipid shell, the resulting FC-NPs measured roughly 107 nanometers, remained stable in the bloodstream, and released their payload only in the acidic environment of endosomes, achieving true synchronized co-delivery.

In mouse models of colorectal cancer, the nanoparticles delivered on their promise. Three intratumoral injections of FC-NPs inhibited MC38 tumor growth by 82 percent, compared with just 31 percent for the free drug mixture, while cutting the required dosing frequency from thrice daily to once daily. Treated tumors flooded with IFN-β, CXCL10, TNF-α, and IFN-γ, and produced markedly more tumor antigen-specific CD8-positive T cells. The efficacy vanished in mice lacking cross-presenting dendritic cells or depleted of CD8-positive T cells, confirming that adaptive antitumor immunity — the downstream product of STING activation — was the engine of the response. Most strikingly, adding anti-PD-L1 antibody to the nanoparticles produced complete tumor rejection in all treated mice, a result neither therapy achieved alone. Because floxuridine is already the standard agent for hepatic artery infusion in colorectal liver metastases, the authors argue that co-delivering CMP in that regional setting offers a direct, actionable path to the clinic, with CMP showing good biosafety in vivo.

Subject of Research: A metabolic strategy in which ribonucleotides amplify fluoropyrimidine-induced mitochondrial DNA release and cGAS–STING activation to potentiate colorectal cancer chemoimmunotherapy

Article Title: Ribonucleotides Amplify Mitochondrial DNA‐Driven cGAS–STING Activation via FdUMP‐ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy

Article References: Wang, C., Zhao, C., Yao, Y., Zou, Z., Shi, A., Feng, Z., Yang, M., Yu, Y., Liu, Y., Rui, X., & Wu, J. (2026). Ribonucleotides Amplify Mitochondrial DNA‐Driven cGAS–STING Activation via FdUMP‐ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy. Advanced Science, Article e77614. https://doi.org/10.1002/advs.77614

Image Credits: AI Generated

DOI: 10.1002/advs.77614

Keywords: cGAS–STING, mitochondrial DNA, ribonucleotides, floxuridine, colorectal cancer, chemoimmunotherapy, lipid nanoparticles, nucleotide metabolism, FdUMP, thymidylate synthase, PD-L1 blockade, CRISPR screen

The researchers began with an unbiased approach designed to let the cells themselves point to the answer. Using a genome-wide CRISPR screen, they systematically disabled every gene in human cells and then flooded the survivors with high levels of cysteine. If a cell lacking a particular gene suddenly became resistant to cysteine’s lethal effects, that gene was likely part of the killing machinery. The screen delivered a striking and somewhat counterintuitive result: the strongest protective hits were not antioxidant enzymes or detoxification pathways, but the mitochondrial iron transporters SLC25A28 and SLC25A37, also known as mitoferrins. These proteins sit in the inner mitochondrial membrane and shuttle iron into the organelle. When the researchers knocked them out, cells tolerated cysteine doses that would otherwise be fatal, indicating that the import of iron into mitochondria is an essential step in cysteine toxicity.

That finding reframed the problem entirely. Rather than acting as a simple chemical toxin that oxidizes or alkylates cellular components, excess cysteine appears to hijack the cell’s own iron logistics. The team showed that limiting mitochondrial iron availability suppresses cysteine-induced cell death and, crucially, prevents the damage that cysteine inflicts on iron–sulfur cluster proteins and on respiration itself. Iron–sulfur clusters are tiny cofactors assembled inside mitochondria and installed into a wide range of proteins, including components of the respiratory chain that generate cellular energy and enzymes that maintain the genome. When their integrity fails, mitochondria falter, energy production collapses, and the cell begins to die.

To understand how a surplus of an amino acid could destabilize iron in the first place, the researchers traced the metal’s movements through the cell. Their experiments revealed that cysteine mobilizes iron from ferritin, the cell’s principal iron storage cage, expanding the cytosolic pool of freely available iron. That liberated iron is then driven into mitochondria through the mitoferrin transporters, causing the organelles to accumulate iron to dangerous levels. This mechanism echoes classical biochemistry: reductants, including thiols, have been known since the 1970s to release iron from ferritin, and in bacteria, high intracellular cysteine was shown more than twenty years ago to promote oxidative DNA damage by fueling the Fenton reaction, in which iron converts hydrogen peroxide into destructive hydroxyl radicals. The new work shows that in human cells, the consequences of this iron release converge specifically on mitochondria.

Why would extra iron inside mitochondria be so lethal? The answer, according to the study, lies in the delicate redox chemistry of the organelle. The researchers found that the balance between reduced and oxidized glutathione, the cell’s master antioxidant couple, becomes critically imbalanced downstream of iron accumulation. Mitochondria normally maintain a robust pool of reduced glutathione, imported through the transporter SLC25A39, to buffer the reactive chemistry of the respiratory chain. When cysteine overload disrupts this balance, iron–sulfur cluster proteins begin to deteriorate, including respiratory chain components and mitochondrial translation factors that depend on these clusters. Proteomic analysis confirmed that cysteine treatment selectively depletes iron–sulfur cluster-containing proteins from the mitochondrial compartment, and respiration measurements showed corresponding losses of basal and maximal oxygen consumption.

The most elegant experiment in the paper demonstrates that this redox collapse is not merely a side effect but a causal driver of death. The researchers engineered cells to express a bacterial enzyme, GshF, that synthesizes glutathione, targeting it either to the cytosol or specifically to mitochondria. Boosting glutathione reductase activity within mitochondria alone restored redox balance downstream of iron accumulation and protected cells from cysteine toxicity by preserving iron–sulfur cluster integrity. Cytosolic glutathione enhancement, by contrast, offered far less protection. In other words, the battle over life and death is fought inside the mitochondrial matrix, where the glutathione pool must keep pace with the iron-driven chemical storm that excess cysteine ignites.

The study also clarifies how this newly defined death pathway differs from the better-known forms of regulated cell death. Ferroptosis, discovered in 2012, occurs when cysteine depletion lowers glutathione, inactivating the lipid-repair enzyme GPX4 and allowing iron-dependent lipid peroxidation to shred cellular membranes. Disulfidptosis, described in 2023, arises under glucose starvation when high cysteine levels promote aberrant disulfide bonds in actin cytoskeleton proteins. The pathway described by Nakamura and colleagues is mechanistically distinct: it requires mitochondrial iron import, proceeds through ferritin mobilization and glutathione redox imbalance, and culminates in the loss of iron–sulfur clusters rather than lipid peroxidation or cytoskeletal collapse. The authors propose that this represents a distinct mitochondrial iron-dependent cell death triggered under conditions of thiol imbalance.

The findings carry weight well beyond basic cell biology. Cells keep their cysteine levels remarkably low, a fact that has long hinted at the molecule’s intrinsic toxicity, and the new work explains why: maintaining low cysteine safeguards mitochondrial iron homeostasis. That principle has clinical echoes. Elevated plasma cysteine has been associated with vascular disease and is disturbed in cirrhosis, and recent studies have shown that cysteine depletion can drive dramatic weight loss by triggering adipose tissue thermogenesis, while dietary cysteine influences intestinal stemness through immune signaling. Cancer adds another layer of relevance. Some tumors, particularly those with NRF2 activation, appear vulnerable to excess cysteine through conjugate formation, and D-cysteine has been shown to impair tumor growth by inhibiting the iron–sulfur cluster assembly enzyme NFS1. A therapy that deliberately pushes cysteine above toxic thresholds, or that blocks mitochondrial glutathione reduction to sensitize cells to thiol stress, could exploit this newly mapped vulnerability.

There are also implications for aging. Earlier work from the same scientific lineage showed that cysteine toxicity drives age-related mitochondrial decline by altering iron homeostasis, and the new mechanistic framework gives that observation a concrete molecular basis: ferritin mobilization, mitoferrin-mediated iron import, and glutathione redox failure inside mitochondria. As organisms age, mitochondrial iron handling becomes increasingly error-prone, and thiol metabolism shifts in ways that could tip vulnerable cells toward this death pathway. Understanding the checkpoints along that route, from ferritin release to SLC25A28 and SLC25A37 activity to mitochondrial glutathione reductase capacity, offers a series of potential intervention points.

What makes the study especially compelling is its demonstration that a nutrient’s protective and poisonous faces are governed by the same underlying chemistry. Cysteine supports iron–sulfur cluster biogenesis when dosed correctly and dismantles it when dosed in excess, with the difference determined by how much iron the mitochondria admit and how much reducing power they retain. The Rockefeller-led team has thus turned a decades-old puzzle into a coherent mechanism, one that connects amino acid metabolism, metal trafficking and redox biology into a single lethal circuit. As researchers now test whether this mitochondrial iron-dependent death operates in tissues and diseases where thiol levels run high, the humble amino acid that every biology student learns to love may gain a reputation as one of the cell’s most dangerous tenants when it overstays its welcome.

Subject of Research: Mechanism of cysteine-induced mitochondrial iron-dependent cell death

Article Title: Cysteine excess triggers a mitochondrial iron-dependent cell death

Article References: Nakamura, T., Inoki, A., Das, N. K., Chen, B., Khan, A., Liu, Y., Uygur, B., Yen, F. S., Unlu, G., Shah, Y. M., & Birsoy, K. (2026). Cysteine excess triggers a mitochondrial iron-dependent cell death. Nature Metabolism. https://doi.org/10.1038/s42255-026-01616-7

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01616-7

Keywords: cysteine, mitochondria, iron homeostasis, cell death, iron–sulfur clusters, glutathione, ferritin, mitoferrin, ferroptosis, redox balance, metabolism, CRISPR screen

The method, described in the journal BMC Bioinformatics by Jack Kamm, Jake Yeung, and William F. Forrest of Genentech, reframes guide assignment as a problem in classical statistics. Rather than fitting an elaborate probabilistic model to the guide count matrix, the authors propose treating the matrix of guide RNA counts across cells as a contingency table. For every cell-guide pair, they construct a two-by-two table that contrasts the counts involving that cell and that guide with all other counts, and then apply Fisher’s Exact Test, a workhorse of categorical data analysis, to ask whether the cell and guide barcodes are statistically associated. A significant association signals that the guide is genuinely present in the cell rather than appearing by chance through sequencing noise.

The elegance of this formulation lies in what it provides automatically. Because Fisher’s Exact Test conditions on the margins of the contingency table, the resulting p-values implicitly normalize for both cell-specific and guide-specific size factors, the uneven sequencing depth that plagues single-cell data. Cells that received more total reads and guides that were more abundant in the library are handled without any explicit normalization step. The method also produces a p-value for every cell-guide pair, giving users a graded measure of confidence rather than a hard binary call, and enabling downstream analyses such as full precision-recall curves when benchmarking alternative cutoffs.

Two statistical subtleties demanded additional innovation. First, because the method performs one test for every cell-guide combination, large screens can involve tens of millions of hypothesis tests. Naive application of standard multiple testing corrections such as the Benjamini-Hochberg procedure would be inappropriate, because the tests are strongly correlated: a cell that tests positive for one guide is less likely to test positive for others, and counts involving the same guide or the same cell share information. The authors developed a multiple testing correction strategy that accounts for this correlation structure, preserving control of the false discovery rate while avoiding the excessive conservatism that would come from ignoring the dependencies.

The second subtlety is a form of confounding that can flip conclusions in exactly the wrong way. Ambient RNA contamination, sometimes called soup or background noise, introduces guide molecules into cells that never received them. If the contamination is not independent across cells and guides, a phenomenon analogous to Simpson’s paradox can arise: an association that appears significant in the aggregate data disappears, or even reverses, once the noise component is considered separately. Fishash addresses this by testing an adjusted odds ratio that replaces the margins involving the focal cell and guide with their noise-based counterparts. To estimate the unobserved noise counts, the method performs an iterative rank-1 Poisson matrix completion: entries that have already been confidently assigned are masked out, the remaining background structure is fit under a Poisson likelihood by alternating updates of guide and cell abundance parameters, and the imputed noise counts feed back into refined p-values. The procedure repeats until the assignments stabilize.

Recognizing that fair comparison of guide assignment methods has been hampered by a lack of realistic test data, the authors also introduced a simulation framework that generates synthetic guide counts under a detailed model of sequencing noise. The simulator draws on the contamination model popularized by the Cellbender software, incorporating latent cell-level factors such as ambient RNA fractions, capture efficiencies, and dropout rates, along with guide-level expression variation. Crucially, the simulations can vary the number of guides in the library and the multiplicity of infection, the average number of guides delivered per cell, allowing benchmarking across the parameter regimes that matter in practice. The code to reproduce all results is publicly available alongside the method itself.

In benchmarks on both simulated and real datasets, Fishash compared favorably with existing approaches in both accuracy and runtime. On simulations varying the number of guides, the method achieved the top median F1 score in the majority of settings, performing particularly well when the guide library was large or guide RNA expression was low. In simulations varying the multiplicity of infection, Fishash remained competitive at low multiplicity, where most cells carry at most one guide, though other methods such as crispat-NB and dcCLEANSER edged ahead at high multiplicity. The authors emphasize that Fishash was conservative in its error control: its observed precision stayed above its nominal lower bound across the sweep, whereas several competing Bayesian and frequentist methods failed to control the false discovery rate at least once across the scenarios tested.

The stress tests also revealed the method’s limits, which the authors report transparently. When extra overdispersion was injected into the noise counts by replacing the Poisson distribution with a Geometric distribution, one of the most extreme overdispersion regimes available, precision dropped for many methods and Fishash no longer controlled the false discovery rate at its nominal five percent level in every scenario. Even so, its F1 scores remained qualitatively similar to the original benchmarks, indicating a competitive balance between precision and recall even under unusually harsh noise. The authors note that the conditional low-rank Poisson structure assumed for background counts is common to many single-cell contamination models, including Cellbender, SoupX, DecontX, and scAR, so the simulation represents a deliberately challenging departure from the assumptions shared across the field.

Practical accessibility was a design priority. Fishash is distributed as an easy-to-use R package on GitHub, and because it relies on exact tests over contingency tables rather than iterative model fitting, it scales comfortably to screens with tens of thousands of cells and guides, where computationally expensive probabilistic approaches can become prohibitive. The software also outputs its test statistic for every entry of the cell-guide matrix, which allows users to visualize the distribution of scores, select alternative significance cutoffs informed by the data, and compute full precision-recall curves during method benchmarking. The work was carried out entirely within Genentech, with the authors crediting colleagues in the company’s AI Biology and Translation department for discussions that shaped the manuscript.

For the growing community running Perturb-seq experiments, the significance of the method is straightforward: guide assignment is the gatekeeper step that determines whether downstream perturbation effects are real or artifacts of misassignment, and errors made here propagate through every subsequent analysis. By combining a classical, well-understood statistical test with modern corrections for multiplicity, confounding, and background contamination, and by packaging the result in fast, open software, Fishash lowers both the computational and conceptual barriers to reliable pooled single-cell screening. As CRISPR screens continue to expand in scale and ambition, tools that trade heavy model fitting for careful, assumption-aware statistics are likely to play an increasingly central role in turning raw sequencing counts into trustworthy biological conclusions.

Subject of Research: A contingency table and Fisher's Exact Test based method for assigning guide RNAs to cells in single-cell pooled CRISPR screens (Perturb-seq)

Article Title: Fishash: a contingency table approach to Perturb-seq guide assignment

Article References: Kamm, J., Yeung, J., & Forrest, W. F. (2026). Fishash: a contingency table approach to Perturb-seq guide assignment. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06631-9

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06631-9

Keywords: Perturb-seq, CRISPR screen, single-cell RNA-seq, guide assignment, Fisher's exact test, Simpson's paradox, multiple testing correction, contingency table, false discovery rate, ambient RNA contamination, functional genomics, BMC Bioinformatics

The study began with a practical problem: researchers have lacked good tools to study the behavior of hepatitis B virus-specific T cells in a physiologically relevant setting. The team used a humanized mouse model carrying the human HLA-A11 molecule to identify a T cell receptor that recognizes HBc141-151, an epitope from the hepatitis B core antigen that is clinically relevant in human patients. This receptor, which the authors call HB-I, allowed them to generate transgenic mice whose entire CD8+ T cell population is specific for a single, human-relevant HBV epitope, providing a tractable platform for dissecting why these cells fail during chronic infection.

With that platform in hand, the researchers turned to an unbiased discovery strategy. Using a whole-genome CRISPR-Cas9 knockout library delivered into HBV-specific T cells, followed by screening under chronic antigen stimulation, they asked which genes, when deleted, would help T cells resist the dysfunctional state that normally develops. The screen converged on Ankrd11, a gene previously known as a chromatin regulator implicated in neural development and in Kabuki-like syndromes, but never before linked to T cell exhaustion. Loss of Ankrd11 consistently produced T cells that proliferated more vigorously and retained stronger effector characteristics.

The mechanistic picture that emerges from the paper is epigenetic. ANKRD11 appears to restrain the accessibility and acetylation of key effector genes. Using ATAC-seq, bulk RNA-seq and CUT&Tag profiling of the histone mark H3K27ac, the team showed that Ankrd11-deficient CD8+ T cells display increased chromatin openness and enhancer acetylation at loci encoding AP-1 family transcription factors, notably Fos and Fosb. Elevated AP-1 activity, in turn, drives a program of effector differentiation: the cells produce more granzyme B and interferon-gamma, resist the immunosuppressive conditions that normally silence them, and maintain function even when interleukin-2, a survival factor, is limiting.

Functionally, the consequences of losing this brake were striking. In mice carrying a replicating HBV plasmid or infected with recombinant HBV vectors, Ankrd11-deficient HBV-specific T cells expanded more robustly, infiltrated the liver more effectively, and drastically reduced serum levels of hepatitis B surface antigen, viral DNA and markers of liver damage. Parallel experiments using a second chronic infection model, lymphocytic choriomeningitis virus clone 13, confirmed the generality of the effect: adoptively transferred Ankrd11-deficient virus-specific P14 T cells showed enhanced granzyme expression, proliferation and viral control in the spleen and blood.

Perhaps the most conceptually interesting finding concerns the differentiation paths that exhausted T cells normally follow. In chronic infection and cancer, antigen-specific CD8+ T cells split into progenitor exhausted T cells, which express the transcription factor TCF-1 and serve as a self-renewing reservoir, and terminally exhausted T cells, which lose TCF-1 and are irreversibly dysfunctional. The authors found that Ankrd11 deficiency accelerates the conversion of progenitor exhausted cells into effector-like exhausted cells, but importantly, the resulting cells are cytotoxic and functional rather than inert. This suggests ANKRD11 does not simply maintain progenitor pools but actively gates how far exhausted cells differentiate toward effector competence.

The study also revealed a distinct route of reprogramming specific to chronic hepatitis B. A large fraction of HBV-specific CD8+ T cells in tolerant mice carries a PD-1-negative, TOX-negative phenotype that has resisted conventional checkpoint-based rescue strategies. When ANKRD11-mediated repression was relieved, these tolerant cells differentiated into PD-1-positive, KLRG1-positive effector cells armed with high granzyme levels, providing an explanation for the improved viral clearance. In other words, ANKRD11 deficiency unlocks an otherwise dormant pool of virus-specific cells that immune checkpoint blockade alone cannot reach.

The antitumor implications were tested directly in cancer models. Ankrd11-deficient CD8+ T cells promoted rejection of implanted tumors, enhanced intratumoral T cell activity, and acted synergistically with immune checkpoint blockade, potentiating the effect of PD-1 pathway inhibition. Given that the exhaustion of tumor-infiltrating lymphocytes is a central cause of immunotherapy failure, a single gene whose deletion reprograms effector differentiation under immunosuppressive conditions is an attractive candidate for therapeutic engineering, for example in chimeric antigen receptor or T cell receptor-engineered cell products. A provisional patent application has been filed based on the findings, underscoring the translational interest.

Caveats remain before ANKRD11 targeting reaches the clinic. ANKRD11 is a broad chromatin regulator with established roles in neural and cardiac development, so systemic inhibition is unlikely to be safe; the therapeutic window will probably lie in ex vivo engineering of T cells or in carefully targeted delivery. It will also be important to determine whether accelerated terminal differentiation comes at the cost of long-term memory formation. Nevertheless, the study delivers a clear conceptual advance: T cell dysfunction in chronic infection and cancer is not merely the product of inhibitory receptor signaling, but is epigenetically authored, and specific chromatin factors such as ANKRD11 can be removed to rewrite that script. For the hundreds of millions of people living with chronic hepatitis B, and for cancer patients whose T cells have gone quiet, that insight opens a new direction for immunotherapy design.

The concept of T cell exhaustion has shaped immunology for two decades. Since the landmark demonstration that chronically stimulated CD8+ T cells can regain function when inhibitory pathways are interrupted, researchers have catalogued a molecular signature of the dysfunctional state, and later work established the transcription factor TOX as a master architect of the exhaustion program, acting at both transcriptional and epigenetic levels. What has remained less clear is whether exhaustion is a fixed fate or a tunable state whose chromatin underpinnings can be deliberately rewritten. The new study adds weight to the second view by identifying a specific chromatin-associated protein whose removal shifts the balance of differentiation toward cytotoxic competence.

The methodological route to this finding is worth noting. Genome-wide CRISPR-Cas9 knockout screens have become a powerful way to uncover genes that constrain or enable T cell behavior, and previous efforts using this approach identified regulators such as REGNASE-1 and Roquin as suppressors of effector expansion and antitumor immunity. The present screen extends this logic into the setting of chronic hepatitis B virus infection, a context in which suppressive cues differ from those in tumors and in which conventional checkpoint blockade has shown only modest clinical benefit. That an unbiased screen converged on a gene with no prior immunological pedigree illustrates how phenotype-first discovery can bypass assumptions rooted in known pathways.

ANKRD11 itself carries an interesting dual history. It was first characterized as a chromatin regulator essential for neural development, and subsequent work showed it controls cardiac neural crest-mediated remodeling of the outflow tract. Its association with a Kabuki-like syndrome in humans reflects the pleiotropic consequences of disturbing a factor that operates broadly across tissues. This background both explains why the protein had escaped attention in immunology and reinforces the caution that any therapeutic interference must be confined to engineered cells rather than delivered systemically.

The AP-1 connection provides a mechanistic bridge to earlier T cell biology. AP-1 family transcription factors, built from Fos and Jun proteins, have long been recognized as immediate-early responders to T cell receptor signaling, and their activity is known to cooperate with other factors to specify effector genes. By showing that ANKRD11 restrains chromatin accessibility and H3K27 acetylation at AP-1 loci, the study suggests a route by which a chromatin regulator can gate a transcriptional program that is otherwise primed and waiting in naive and exhausted cells alike.

The authors have deposited the datasets underlying these conclusions in public repositories: bulk RNA-seq data under accession GSE299520, ATAC-seq data under GSE299519, and CUT&Tag data under GSE299521, with source data provided alongside the paper. No original code was generated. This transparency should allow groups working on T cell engineering to interrogate the chromatin changes directly and to test whether similar ANKRD11-sensitive programs operate in human tumor-infiltrating lymphocytes, a necessary step before the findings can inform next-generation cell therapy design.

Subject of Research: Epigenetic regulation of CD8+ T cell dysfunction in chronic viral infection and cancer

Article Title: ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer

Article References: Xu, W., Guo, J., Cao, X., Li, L., Xiao, P., Zhang, X., Jin, Q., Zhang, F., Hou, B., Li, M., & Zhou, X. (2026). ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer. Nature Immunology. https://doi.org/10.1038/s41590-026-02652-x

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02652-x

Keywords: ANKRD11, CD8+ T cells, T cell exhaustion, chronic hepatitis B, epigenetics, immunotherapy, CRISPR screen, AP-1 transcription factors, granzyme B, immune checkpoint blockade, tumor immunity, T cell receptor